5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Vinayak Doraiswamy, the Chief Scientific Officer of AtriCure , Inc. (NASDAQ:ATRC), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Doraiswamy disposed of 2,500 shares of AtriCure common stock on May 28, 2025, at a price of $33.44 per share. This transaction amounted to a total value of $83,600. The sale occurred as AtriCure’s stock has shown significant momentum, posting a 53.1% return over the past year. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 4.11, indicating robust liquidity.
Following this sale, Doraiswamy retains ownership of 73,550 shares in the company. The sale was reported on May 30, 2025, and reflects Doraiswamy’s ongoing involvement in managing his investment in the company. With a market capitalization of $1.7 billion and an overall Financial Health Score of "GOOD" according to InvestingPro, which offers comprehensive analysis and 8 additional key insights about AtriCure’s current market position and future prospects.
In other recent news, AtriCure Inc. reported its first-quarter 2025 earnings, surpassing expectations with an adjusted loss per share of $0.14, better than the projected loss of $0.22. The company’s revenue reached $123.6 million, slightly above the anticipated $123.08 million, marking a 13.6% year-over-year growth. AtriCure has confirmed its revenue outlook for the year and raised its adjusted EBITDA and EPS forecasts. Needham analysts adjusted their stance on AtriCure, reducing the price target to $44.00 from $51.00, while maintaining a Buy rating, citing a contraction in peer multiples affecting valuation perspectives. JMP Securities, on the other hand, reiterated a Market Outperform rating with a $60.00 price target, highlighting AtriCure’s progress towards sustainable revenue growth driven by product development and improved operating leverage. The company’s Pain Management business saw a notable 39% year-over-year growth, supported by the rapid adoption of new product launches. Looking ahead, AtriCure plans to introduce additional products like CryoXT for Pain Management and AtriClip PRO-Mini for Appendage Management, which are expected to bolster its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.